May 6, 2020 / 2:08 PM / 22 days ago

BRIEF-Bausch Health And Alfasigma Announce Resolution Of Xifaxan Intellectual Property Litigation

May 6 (Reuters) - Bausch Health Companies Inc:

* BAUSCH HEALTH AND ALFASIGMA ANNOUNCE RESOLUTION OF XIFAXAN® INTELLECTUAL PROPERTY LITIGATION

* BAUSCH HEALTH - SALIX PARTIES AGREED TO RESOLVE OUTSTANDING IP LITIGATION WITH SANDOZ INC., REGARDING XIFAXAN (RIFAXIMIN) 550 MG TABLET

* BAUSCH HEALTH - SALIX PARTIES WILL GRANT SANDOZ A NON-EXCLUSIVE LICENSE EFFECTIVE JAN. 1, 2028 TO ITS IP RELATING TO XIFAXAN 550 MG TABLETS IN U.S.

* BAUSCH HEALTH COMPANIES INC - SANDOZ ACKNOWLEDGES VALIDITY OF LICENSED PATENTS. FINAL PATENT EXPIRY ON XIFAXAN 550 MG TABLETS IS OCTOBER 2029

* BAUSCH HEALTH COMPANIES INC - LITIGATION BETWEEN PARTIES RELATED TO XIFAXAN WILL BE DISMISSED, AND ALL IP PROTECTING XIFAXAN REMAINS INTACT Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below